CN119317446A - 用于预防covid-19的重组新城疫病毒和免疫原性组合物 - Google Patents

用于预防covid-19的重组新城疫病毒和免疫原性组合物 Download PDF

Info

Publication number
CN119317446A
CN119317446A CN202380026690.5A CN202380026690A CN119317446A CN 119317446 A CN119317446 A CN 119317446A CN 202380026690 A CN202380026690 A CN 202380026690A CN 119317446 A CN119317446 A CN 119317446A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
protein
seq
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026690.5A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·帕雷斯
阿道夫·加西亚·塞斯特
佛罗莱恩·克拉默
孙薇娜
艾琳·冈萨雷斯·多明格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of CN119317446A publication Critical patent/CN119317446A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380026690.5A 2022-03-10 2023-03-09 用于预防covid-19的重组新城疫病毒和免疫原性组合物 Pending CN119317446A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10
US63/318,640 2022-03-10
PCT/US2023/064063 WO2023173032A2 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Publications (1)

Publication Number Publication Date
CN119317446A true CN119317446A (zh) 2025-01-14

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026690.5A Pending CN119317446A (zh) 2022-03-10 2023-03-09 用于预防covid-19的重组新城疫病毒和免疫原性组合物

Country Status (11)

Country Link
US (1) US20250186578A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489779A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509352A (cg-RX-API-DMAC7.html)
KR (1) KR20240161963A (cg-RX-API-DMAC7.html)
CN (1) CN119317446A (cg-RX-API-DMAC7.html)
AU (1) AU2023231285A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245533A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002683A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012344A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024011049A (cg-RX-API-DMAC7.html)
WO (1) WO2023173032A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
EP4408463A4 (en) * 2021-09-30 2026-03-18 Icahn School Med Mount Sinai Recombinant Newcastle Disease Virus Expressing a SARS-CoV-2 Delta Variant Spike Protein and Its Uses

Also Published As

Publication number Publication date
KR20240161963A (ko) 2024-11-13
US20250186578A1 (en) 2025-06-12
EP4489779A2 (en) 2025-01-15
WO2023173032A3 (en) 2023-10-12
MX2024011049A (es) 2024-09-18
WO2023173032A2 (en) 2023-09-14
CL2024002683A1 (es) 2025-01-03
CA3245533A1 (en) 2023-09-14
JP2025509352A (ja) 2025-04-11
AU2023231285A1 (en) 2024-07-25
CO2024012344A2 (es) 2024-12-30
EP4489779A4 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
JP6900437B2 (ja) パラインフルエンザウイルス5型ベースのワクチン
CN103442731B (zh) 表达系统
ES2858315T3 (es) Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
US9701723B2 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
JP2023524990A (ja) SARS-CoV-2スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN101636177A (zh) 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗
CN104962581B (zh) 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株
KR20210005090A (ko) 키메라 벡터
JP5730204B2 (ja) インフルエンザm2由来の改変ペプチドワクチン
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
US20240199705A1 (en) Chimeric newcastle disease virus expressing apmv hn and f proteins
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
WO2015084838A1 (en) Recombinant respiratory syncytial virus g protein fragments

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination